Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02436460 · ClinicalTrials.gov registry record · Phase 1
A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
A Phase 1 study, sponsored by AbGenomics B.V Taiwan Branch.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT02436460 is a Phase 1 study that was terminated before completion, run by AbGenomics B.V Taiwan Branch. The registered enrollment target is 4 participants.
The verdict
NCT02436460, a Phase 1 study, was terminated before completion, sponsored by AbGenomics B.V Taiwan Branch.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study is to establish the safety, determine if there is an improvement in steroid refractory acute graft-vs-host disease (aGvHD) compared to historical cohorts, and determine the changes of aGvHD-associated T-cell clones in patients with steroid-refractory aGVHD following allogeneic hematopoietic cell transplantation administered AbGn-168H once weekly for 4 weeks.
Interventions
- BIOLOGICAL AbGn-168H
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02436460
The ClinicalTrials.gov registry entry for NCT02436460 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbGenomics B.V Taiwan Branch, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AbGn-168H is the first listed.
NCT02436460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02436460 about?
NCT02436460 is a clinical study titled "A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant". This study is to establish the safety, determine if there is an improvement in steroid refractory acute graft-vs-host disease (aGvHD) compared to historical cohorts, and determine the changes of aGvHD-associated T-cell clones in patients with steroid-refractory aGVHD following allogeneic hematopoiet...
What is the current status of trial NCT02436460?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2015-05. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02436460?
The interventions under investigation include: AbGn-168H (BIOLOGICAL).
Who is sponsoring clinical trial NCT02436460?
This trial is sponsored by AbGenomics B.V Taiwan Branch, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.